REGENXBIO to Present at Upcoming Investor Conferences

ROCKVILLE, Md., Oct. 03, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will present at the following October investor conferences:

Chardan Inaugural Gene Therapy ConferenceDate: Tuesday, October 10, 2017Location: The Westin New York Grand Central HotelFireside chat: Tuesday, October 10, 2017 at 9:30 a.m. ETPanel: Gene Therapies: Pricing and Other Commercial Considerations; Tuesday, October 10, 2017 at 4:15 p.m. ET

Jefferies Gene Therapy Technology Investor SummitDate: Thursday, October 12, 2017Location: The Westin New York Grand Central HotelFireside chat: Thursday, October 12, 2017 at 3:10 p.m. ET

A live webcast of each presentation can be accessed in the Investors section of REGENXBIO’s website at www.regenxbio.com. An archived replay of each webcast will be available on the same website for approximately 30 days following the presentation. In addition, REGENXBIO senior management will be holding one-on-one meetings at each of the conferences.

About REGENXBIO

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.

CONTACT:

Investors Natalie Wildenradt, 646-681-8192 [email protected]

Media Adam Pawluk, 202-591-4063 [email protected]

You May Also Be Interested In

• Narravero Named a Market Shaper in the 2026 Gartner® Emerging Market Quadrant for Digital Product Passport
• The Next Pepe Coin Is Already Live and Its Listing Will End the Presale Entry Forever
• BioNxt Advances Cladribine Clinical Program with Completion of the Investigational Medicinal Product Dossier (IMPD) Ahead of Human Clinical Studies